FDA Places Clinical Hold on Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 Trial of Schizophrenia Drug Evenamide in the U.S.
Background of the Phase 3 Clinical Trial Hold in the U.S.
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on the U.S. portion of Newron Pharmaceuticals' global Phase 3 trial, 'ENIGMA-TRS 2,' for its schizophrenia drug candidate, Evenamide. This action was triggered by a case of sudden death in a patient at a clinical site outside the U.S. To ensure patient safety, the FDA proactively halted new patient enrollment in the U.S. While the investigators and the independent Data and Safety Monitoring Board (DSMB) concluded that the death was unlikely related to the drug, the FDA is requesting additional safety data before allowing the trial to resume in the U.S.
Mechanism of Action of Evenamide and its Differentiated Market Positioning
Evenamide has a novel mechanism of action (MOA) by blocking voltage-gated sodium channels (VGSC) and normalizing abnormal glutamate release. Unlike existing treatments that primarily target dopamine D2 receptors, Evenamide is designed for patients with treatment-resistant schizophrenia (TRS). The schizophrenia drug market is estimated at $8.5 billion to $11.2 billion annually, and there is still a significant unmet medical need. The emergence of a new mechanism of action has generated considerable interest in the market.
Clinical Diversification and Regulatory Risk Management Strategies
Newron Pharmaceuticals has stated that the clinical hold is limited to new patient enrollment in the U.S., and the trial continues at approved sites in other countries, such as India and Argentina. Additionally, the separate Phase 3 trial, 'ENIGMA-TRS 1,' is ongoing in 21 countries worldwide without interruption, minimizing the risk of a complete pipeline disruption. Newron Pharmaceuticals plans to promptly submit the additional safety data requested by the FDA and seeks to obtain approval to resume the U.S. trial as soon as possible.
Competitive Landscape in the Schizophrenia Market and Future Outlook
Recently, BMS's muscarinic agonist, Cobenfy, has received FDA approval and is entering the commercial stage. However, AbbVie's Emraclidine failed to meet its primary endpoint in a Phase 2 trial. In this competitive environment, the clinical hold on Newron Pharmaceuticals' Evenamide poses a risk of delaying its market entry. Therefore, Newron Pharmaceuticals must quickly restore market confidence by demonstrating robust cardiovascular and central nervous system (CNS) safety data.
The FDA's decision to place a clinical hold on Newron Pharmaceuticals' Phase 3 ENIGMA-TRS 2 trial of Evenamide in the U.S. represents a significant short-term setback, potentially delaying the launch of the drug in the global schizophrenia market, which is worth over $8.5 billion annually. With BMS's Cobenfy recently approved and AbbVie's Emraclidine failing in Phase 2, it is crucial for Evenamide to quickly resolve the clinical hold and solidify its position as a differentiated treatment for treatment-resistant schizophrenia (TRS). In the medium to long term, Newron Pharmaceuticals must objectively demonstrate the safety of Evenamide, particularly regarding cardiovascular and other adverse events, to maintain its partnerships with global licensing partner EA Pharma and regional partners such as Myungin Pharmaceutical. This situation underscores the rigorous safety standards of regulatory agencies in the development of neuropsychiatric drugs and highlights the importance of robust toxicity and safety screening in the design of CNS clinical trials.
Source: FierceBiotech (rss)